In the BioHarmony Drug Report Database
Bromocriptine
Cycloset, Parlodel (bromocriptine) is a small molecule pharmaceutical. Bromocriptine was first approved as Cycloset on 1982-01-01. It is used to treat acromegaly, adenoma, amenorrhea, galactorrhea, and hyperprolactinemia amongst others in the USA. The pharmaceutical is active against D(2) dopamine receptor, D(3) dopamine receptor, and D(4) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 6, D(1B) dopamine receptor, alpha-2A adrenergic receptor, 5-hydroxytryptamine receptor 1D, alpha-2C adrenergic receptor, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2B, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1B, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, 5-hydroxytryptamine receptor 7, and cytochrome P450 3A4. Bromocriptine mesylate’s patents are valid until 2032-04-30 (FDA).
Trade Name
|
Cycloset, Parlodel |
|---|---|
Common Name
|
bromocriptine |
ChEMBL ID
|
CHEMBL493 |
Indication
|
acromegaly, adenoma, amenorrhea, galactorrhea, hyperprolactinemia, hypogonadism, infertility, neuroleptic malignant syndrome, parkinson disease |
Drug Class
|
Image (chem structure or protein)